326 related articles for article (PubMed ID: 15713906)
1. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
6. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
7. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
8. An atypical variant of Fabry's disease in men with left ventricular hypertrophy.
Nakao S; Takenaka T; Maeda M; Kodama C; Tanaka A; Tahara M; Yoshida A; Kuriyama M; Hayashibe H; Sakuraba H
N Engl J Med; 1995 Aug; 333(5):288-93. PubMed ID: 7596372
[TBL] [Abstract][Full Text] [Related]
9. Cardiac manifestations of Anderson-Fabry disease in children and adolescents.
Kampmann C; Wiethoff CM; Whybra C; Baehner FA; Mengel E; Beck M
Acta Paediatr; 2008 Apr; 97(4):463-9. PubMed ID: 18363956
[TBL] [Abstract][Full Text] [Related]
10. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
11. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
12. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
13. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
Weidemann F; Breunig F; Beer M; Sandstede J; Störk S; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Eur Heart J; 2005 Jun; 26(12):1221-7. PubMed ID: 15728649
[TBL] [Abstract][Full Text] [Related]
14. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
16. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
17. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
19. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
20. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
